医学
糖尿病
重症监护医学
疾病
健康福利
生物技术
生物信息学
生物
内科学
传统医学
内分泌学
作者
Miriam Cabello-Olmo,Miriam Araña,Raquel Urtasun,Ignacio Encı́o,Miguel Barajas
出处
期刊:Foods
[Multidisciplinary Digital Publishing Institute]
日期:2021-07-08
卷期号:10 (7): 1590-1590
被引量:42
标识
DOI:10.3390/foods10071590
摘要
In the last decade, the gastrointestinal microbiota has been recognised as being essential for health. Indeed, several publications have documented the suitability of probiotics, prebiotics, and symbiotics in the management of different diseases such as diabetes mellitus (DM). Advances in laboratory techniques have allowed the identification and characterisation of new biologically active molecules, referred to as “postbiotics”. Postbiotics are defined as functional bioactive compounds obtained from food-grade microorganisms that confer health benefits when administered in adequate amounts. They include cell structures, secreted molecules or metabolic by-products, and inanimate microorganisms. This heterogeneous group of molecules presents a broad range of mechanisms and may exhibit some advantages over traditional “biotics” such as probiotics and prebiotics. Owing to the growing incidence of DM worldwide and the implications of the microbiota in the disease progression, postbiotics appear to be good candidates as novel therapeutic targets. In the present review, we summarise the current knowledge about postbiotic compounds and their potential application in diabetes management. Additionally, we envision future perspectives on this topic. In summary, the results indicate that postbiotics hold promise as a potential novel therapeutic strategy for DM.
科研通智能强力驱动
Strongly Powered by AbleSci AI